Indinavir plasma protein binding in HIV-1-infected adults

AIDS

Volumn 14, Issue 15, 2000, Pages 2293-2297

  Anderson, P L ^a   Brundage, R C ^a   Bushman, L ^a   Kakuda, T N ^a   Remmel, R P ^a   Fletcher, C V ^a  

^a 7 151 Weaver Densford Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; BLOOD PROTEINS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PROTEIN BINDING;

EID: 0033765250     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200010200-00010     Document Type: Article

References (33)

1. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
2. Influence of protein binding and use of unbound drug concentrations
3. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151
4. A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its intracellular uptake
5. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor
6. Pharmacologic basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir
7. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy
8. Indinavir concentrations and antiviral effect
9. Diurnal concordance of human platelet serotonin content and plasma alpha-1-acid glycoprotein concentration
10. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)
11. Mini review: Recent developments in HIV protease inhibitor therapy
12. In vitro effect of alpha1-acid glycoprotein on the anti-Human Immunodeficiency Virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
13. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
14. The effect of increasing alpha-1 acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors
15. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein
16. Pharmacodynamics of HIV-1 protease inhibitors
17. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
18. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
19. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
20. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
21. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
22. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
23. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
24. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
25. Resistance, fitness, adherence, and potency: Mapping the paths to virologic failure